Xintiandi released its 2026 interim report. First-half net profit attributable to the parent was 60.77 million yuan, down 22.1% year on year, while operating revenue was 397 million yuan, up 10.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 54.72 million yuan, down 23.8% year on year. Net operating cash flow was 6.98 million yuan, down 79.0% year on year. Earnings per share were 0.155 yuan. In the second quarter, operating revenue was 190 million yuan, up 36.7% year on year, and net profit attributable to the parent was 24.67 million yuan, up 14.9% year on year. As of the end of the second quarter, total assets were 1.754 billion yuan, down 1.4% from the end of the previous year, and net assets attributable to the parent were 1.534 billion yuan, down 1.1% from the end of the previous year. The company said its main business has not undergone major changes, and it is implementing a new strategy-driven development model to build a modern platform-based company. In the pharmaceutical intermediates business, the main products are the levophenylglycine series and the p-toluenesulfonic acid series. In the active pharmaceutical ingredients business, 15 products have been approved for registration in China, and the formulations business is also advancing integrated development.
New Palace International Co LtdHenan Newland Pharmaceutical Co. Ltd. AFirst-half net profit attributable to parent fell 22.1% year on year, with net cash flow down 79.0%.
